Close Menu
Opinion

EMA’s CHMP Shows Positive Opinion for Durvalumab/tremelimumab Combination in Liver and Lung Cancer

Delbert Williams IIBy No Comments3 Mins Read

[ad_1]

The European Union recommends that the combination of durvalumab and tremelimumab be approved for the treatment of advanced liver and lung cancer.

According to a press release from AstraZeneca, the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion on the combination of durvalumab (Infinzi) and tremelimumab (Injudo) to treat advanced lung and liver cancer. I was.1

The liver cancer indication for this combination was supported by results from the Phase 3 HIMALAYA trial (NCT03298451). The trial highlighted overall survival of 16.43 months with tremelimumab monotherapy and prophylactic durvalumab, 16.56 months with durvalumab alone and 13.77 months with sorafenib.2

“The combination of [tremelimumab] When [durvalumab] Overall survival was significantly improved without increased risk of severe hepatotoxicity or bleeding. This is an important consideration for these patients, who often have advanced disease. ‘ said a professor of internal medicine at Navarre and the University of Navarre School of Medicine in a press release.

Additionally, data from the phase 3 POSEIDON trial (NCT03164616) support the use of durvalumab plus tremelimumab and chemotherapy, with investigators reporting a median progression-free survival of 5.5 months versus , reported 4.8 months for the three-drug regimen and chemotherapy, respectively.3

“Metastatic non-small cell lung cancer remains a complex and devastating diagnosis, and new life-prolonging treatment options remain urgently needed,” said the Department of Thoracic Oncology, Hospitalier University Vaudois, Lausanne, Switzerland. The Medical Oncology Service and Chair said in a press release. “The latest data from the POSEIDON trial [tremelimumab] add to [durvalumab] and chemotherapy, supporting the important role of this novel combination for patients with metastatic non-small cell lung cancer in Europe. ”

of FDA-approved durvalumab and tremelimumab In October 2022, I will treat unresectable hepatocellular carcinoma, a type of liver cancer, Tremelimumab, Durvalumab, and Platinum-Based Chemotherapy Approved I was treated for advanced non-small cell lung cancer in November 2022.4,5

References

  1. The combination of Imfinzi and Imjudo has been recommended for EU approval by the CHMP for the treatment of advanced liver and lung cancer. news release. AstraZeneca. December 19, 2022. Accessed December 19, 2022. https://bit.ly/3v2TLR2
  2. Abou-Alfa G, Lau G, Kudo M and others: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma The New England Journal of Medicine N Engl J Med Evid.2022:1(8).doi:10.1056/EVIDoa2100070
  3. Johnson M, Cho BC, Luft A, etc. Durvalumab with or without tremelimumab with chemotherapy as first-line therapy for metastatic non-small cell lung cancer: the phase III POSEIDON trial. J Clin On CallPublished online November 3, 2022. doi:10.1200/JCO.22.00975
  4. The combination of Imjudo (tremelimumab) and Imfinzi is approved in the United States for patients with unresectable liver cancer. news release. AstraZeneca. October 24, 2022. Accessed December 19, 2022. https://bit.ly/3Fbwx1w
  5. The FDA has approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer. news release. FDA. November 10, 2022. Accessed December 19, 2022. https://bit.ly/3Us5sf8

[ad_2]

Source link

Share.

Born in the early 80s in Milwaukee, Wisconsin, Delbert Williams II has always had a passion for writing. Even in high school, he earned excellent grades in English and writing classes. After attending John Marshall High School, he graduated from Project Stay Alternative High School in Milwaukee. From there, Delbert attended Milwaukee Area Technical College, where he studied music and communications. While he enjoyed these fields, his love for writing remained strong. In 2019, Delbert founded Hard Stack Street Mag, a publication that quickly gained a following for its unique and engaging content. As the founder and editor-in-chief of the magazine, he has worked tirelessly to produce quality articles that cover a wide range of topics, including music, art, culture, and politics. Now 42 years old, Delbert continues to pursue his passion for writing and journalism. Through Hard Stack Street Mag, he has created a platform that allows him to share his voice and perspective with readers from all over the world. With a strong background in writing and a deep understanding of the power of storytelling, Delbert Williams II is a writer to watch. He is dedicated to producing content that is both informative and engaging, and he is committed to using his platform to shine a light on important issues that are often overlooked by mainstream media.

Related Posts

Add A Comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.